Healthcare
Tempest Therapeutics, Inc.(TPST)
Live Price
Offline$1.25
-1.57% today
1Y Change
-81.46%
Window
Jun 23, 2025 โ Jun 9, 2026
- Market Cap
- $10.00M
- Revenue Growth
- 0.0%
- EPS Growth
- -322.0%
- Dividend Yield
- 0.0%
Coverage: 242 bars ยท Jun 23, 2025 โ Jun 9, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Tempest Therapeutics, Inc. (TPST) is a Healthcare stock with a market cap of $10.00M and listed on NASDAQ. The stock last traded around $1.25 and down 81.5% across the available one-year price window (Jun 23, 2025 โ Jun 9, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -322.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -322.0%, free cash flow +19.8% with operating margin 0.0% and ROIC -179.5%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TPST price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -322.0%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -5.7% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | โ | -4.2% | -7.3% | โ |
2026 Mar 30, 2026 | +0.0% | +7.9% | +2.6% | +11.2% |
2025 Nov 5, 2025 | +75.8% | -4.1% | -12.6% | -65.6% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TPST
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TPST Max Drawdown
-89.26%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TPST and SPY.
Company Overview
Tempest Therapeutics, Inc.
NASDAQ Capital Market
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
- Leadership
- Matthew Angel
- IPO Date
- Nov 12, 2012
- Employees
- 24
- Street Address
- 7000 Shoreline Court
- Mailing
- Brisbane, CA, 94080
- Region
- Brisbane, CA, US
- Reporting Currency
- USD
- Investor Line
- 415 798 8589
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 1.3
Growth
- Revenue
- 0.0%
- EPS
- -322.0%
- Free Cash Flow
- +19.8%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -309.6%
- ROIC
- -179.5%
Balance Sheet
- Debt/Equity
- 1.22
- Current Ratio
- 2.50
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.